A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals

Autor: David Shum, Seung Kew Yoon, Marc Peter Windisch, Soonju Park, Eva Zusinaite, Eunji Jo, Denis E. Kainov, Jaewon Yang, Pil Soo Sung, Alexander König

Publikováno v: JHEP Reports
JHEP Reports, Vol 3, Iss 4, Pp 100296-(2021)

Background & Aims Chronic hepatitis B is an incurable disease. Addressing the unmet medical need for therapies has been hampered by a lack of suitable cell culture models to investigate the HBV life cycle in a single experimental setup. We sought to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2d39818aec9a96715b2a465ff2da762
https://hdl.handle.net/11250/3045132

In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach

Autor: Hrithik Praveen, Yiming Zhang, Rory A. Greer, Yuhua Song, Yuwei Song

Publikováno v: European Journal of Pharmaceutical Sciences

Aims Cell surface binding immunoglobin protein (csBiP) is predicted to be susceptible to SARS-CoV-2 binding. With a substrate-binding domain (SBD) that binds to polypeptides and a nucleotide-binding domain (NBD) that can initiate extrinsic caspase-de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff682ee399a7f2cb736647a22b9c519c
https://pubmed.ncbi.nlm.nih.gov/33617948

Advances in the research on the targets of anti-malaria actions of artemisinin

Autor: Shengnan Shen, Jianbin Zhang, Yingke He, Qian Liu, Jigang Wang, Xing Zhang, Yinbao Li, Yin-Kwan Wong, Tianyu Zhong, Jing Yang

Publikováno v: Pharmacology & Therapeutics

Malaria has been a global epidemic health threat since ancient times. It still claims roughly half a million lives every year in this century. Artemisinin and its derivatives, are frontline antimalarial drugs known for their efficacy and low toxicity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060ae5b2926a7cabc900f6edbb1c631d
https://doi.org/10.1016/j.pharmthera.2020.107697

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.

Autor: Alsoud D; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research in Gastrointestinal Disorders (TARGID) - IBD Unit, Leuven, Belgium., Vermeire S; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research in Gastrointestinal Disorders (TARGID) - IBD Unit, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium., Verstockt B; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research in Gastrointestinal Disorders (TARGID) - IBD Unit, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.

Publikováno v: Current research in pharmacology and drug discovery [Curr Res Pharmacol Drug Discov] 2022 Jan 26; Vol. 3, pp. 100089. Date of Electronic Publication: 2022 Jan 26 (Print Publication: 2022).

A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals.

Autor: Yang J; Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam-si, South Korea., König A; Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam-si, South Korea., Park S; Screening Discovery Platform, Institut Pasteur Korea, Seongnam-si, South Korea., Jo E; Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam-si, South Korea., Sung PS; Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.; Catholic University Liver Research Center, The Catholic University of Korea, Seoul, South Korea., Yoon SK; Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.; Catholic University Liver Research Center, The Catholic University of Korea, Seoul, South Korea., Zusinaite E; Institute of Technology, University of Tartu, Tartu, Estonia., Kainov D; Institute of Technology, University of Tartu, Tartu, Estonia.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Shum D; Screening Discovery Platform, Institut Pasteur Korea, Seongnam-si, South Korea., Windisch MP; Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam-si, South Korea.; Division of Bio-Medical Science and Technology, University of Science and Technology, Daejeon, South Korea.

Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2021 Apr 30; Vol. 3 (4), pp. 100296. Date of Electronic Publication: 2021 Apr 30 (Print Publication: 2021).